The unliganded aryl hydrocarbon receptor (AHR) is found in a complex with other proteins including the 90-kDa heat shock protein (Hsp90) and a 37-kDa protein we refer to as ARA9. We found that the three tetratricopeptide repeats found in the COOH terminus of ARA9 are necessary and sufficient for interaction with the AHR complex. Conversely, the AHR's "repressor"/Hsp90 binding domain is required for interaction with ARA9. Because ARA9 closely resembles the 52-kDa FK506-binding protein (FKBP52), found in the unliganded glucocorticoid receptor (GR) complex, we compared the binding specificities of ARA9 and FKBP52 for AHR and GR. In co-immunoprecipitation experiments, ARA9 specifically associated with AHR-Hsp90 complex but not with GRHsp90 complexes. In addition, ARA9 showed a greater capacity than FKBP52 to associate with AHR-Hsp90 complexes. The biological importance of this interaction was suggested by the observation that in a yeast expression system ARA9 expression enhanced the response of AHR to the agonist ␤-napthoflavone, decreasing the EC 50 by greater than 5-fold and increasing the maximal response 2.5-fold. In contrast, co-expression of FKBP52 had no effect on AHR signaling. In addition, although ARA9 contains a domain similar to that found in other FK506-binding proteins, ARA9 binding to 3 H-FK506 could not be detected. Finally, we have characterized the developmental and expression pattern of ARA9 in the developing mouse embryo and mapped the ARA9 locus to human chromosome 11q13.3.
LEU-marked expression plasmid with a TP1 promoter. The plasmid pGAD424 is a 2-m LEU-marked vector for construction of GAL4 transcriptional activation domain fusion proteins (13) . The plasmid pBTMAHRN⌬166 (PL703) was constructed by subcloning the EcoRI fragment of pEGAHRN⌬166 (PL700) into the EcoRI site of pBTM116 (14) . The plasmid pGRNLxC (PL474) is a bacterial expression vector which contains the full-length GR cDNA with the DNA-binding domain replaced in context with the bacterial LexA DNA-binding domain (15) . The plasmid pY2NLxC (PL740) was constructed by amplifying PL474 with the primers OL303 and OL304. The product was cloned into PGEM-Teasy (Promega) (PL734), and the BamHI fragment was subcloned into the BamHI site of pYPGE2 to yield PL740. The plasmids pAHRN⌬130, pAHRN⌬287, pSportAHR, pSportARNT, pSportAHRC⌬237, pSportAHRC⌬313, pSportAHRC⌬425, pSportAHRC⌬458, and pSportAHRC⌬516 have all been previously described (5, 7, 16) . The full-length ARA9 cDNA was amplified from PL580 (7) with OL824 and OL813 and cloned into the EcoRI site of pSV-SPORT (Life Technologies, Inc.) to make pSportARA9 (PL613). The plasmid pYXARA9 (PL810) was constructed by subcloning the full-length ARA9 cDNA from PL613 into the EcoRI site of pYX242. The plasmid pET17b-ARA9 (PL799) was constructed by amplifying PL580 with OL867 and OL838 followed by BglII digestion and the resultant fragment subcloned into the BamHI site of the pET-17b vector (Novagen). The plasmid pET17b-FKBP52 (PL947) was constructed by amplifying FKBP52 from pGEM7Zf-FKBP52 (17) with OL963 and OL1066 and subcloned into the PGEM-T easy vector. The resulting clone was digested with EcoRI and subcloned into the EcoRI site of the pET-17b vector to generate PL947. The carboxyl-terminal deletion of ARA9 was constructed by amplifying PL580 with OL1151 and OL814 and cloning of the fragment into PGEM-T easy. The resulting plasmid was digested with EcoRI and the fragment was subcloned into the corresponding site of pET-17b to create pARA9⌬C (PL1005). The amino-terminal deletion of ARA9 was created in a similar fashion using OL1152 and OL813 to create pARA9⌬N (PL1004). Plasmids pYXFKBP52 and pGADFKBP52 were designed to express the full-length FKBP52 and an FKBP52-GAL4-TAD fusion in yeast. They were constructed by amplifying the FKBP52 cDNA from pGEM7Zf-FKBP52 with OL963 and OL803 and cloning it into PGEM-Teasy. The BamHI fragment was then subcloned into the BamHI site of pYX242 or pGAD424. The plasmid pSportAHR⌬290 -491, PL248, was constructed by subcloning the NotI/HindIII fragment of the murine AHR into the corresponding sites of pSportAHRC⌬516.
Co-immunoprecipitation Assays-For AHR domain mapping, proteins were expressed in vitro using the TNT-coupled rabbit reticulocyte lysate system (Promega). In these experiments, the full-length ARA9 protein was expressed in the presence of [ 35 S]methionine for detection by autoradiography. In our hands, this expression system typically produces approximately 1 fmol of 35 S-labeled protein per 5 l of reaction. Protein complexes were formed by mixing 5 l of the appropriate in vitro translated proteins in a 1.5-ml microcentrifuge tube containing 500 l of MENG buffer (25 mM MOPS, 0.025% NaN 3 , 1 mM EGTA, 10% (v/v) glycerol, 15 mM NaCl, 1 mM dithiothreitol, 0.1% (v/v) Nonidet P-40, pH 7.5), then incubated for 90 min at 4°C. Immunoprecipitations were performed as described previously, using either BEAR-1 or G1295 as the primary antibody (7, 18) .
Bacterial Expression-The ARA9 and FKBP52 proteins tagged with the T7 peptide (PL799, PL1004, PL1005 and PL947) were expressed in BL21(DE3) bacteria (Novagen). The T7 tag is an 11-amino acid peptide, MASMTGGQQMG, that facilitates detection and purification of the recombinant protein using anti-T7 antibodies (Novagen). Saturated cultures were used to inoculate Luria broth growth media supplemented with 0.4 mM isopropyl-1-thio-␤-D-galactopyranoside and 100 g/ml ampicillin. The bacteria were allowed to grow an additional 4 h at 37°C and pelleted by centrifugation at 5000 ϫ g for 5 min. The pellet was resuspended in bind/wash buffer (4.29 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , 2.7 mM KCl, 0.137 M NaCl, 0.1% (v/v) Tween, and 0.002% (w/v) NaN 3 ). The resulting mixture was disrupted using 4 ϫ 15-s sonic pulses on ice. Insoluble debris was removed by centrifugation at 12,000 ϫ g for 20 min at 4°C. The supernatant was passed through a 0.45-m filter and protein concentrations determined by the BCA protein assay (Pierce). The bacterial expression of FKBP52 and ARA9 was confirmed by SDS-PAGE followed by both Coomassie stain and Western blot analysis with an anti-T7 peptide antibody (Novagen). Immunoprecipitations of complexes with either AHR or Hsp90 were performed in MENG buffer as above, using anti-T7-agarose (Novagen). The complexes were then precipitated and analyzed by SDS-PAGE and autoradiography.
Purified ARA9 was prepared from BL21 cells that had been induced by the strategy described above. Following induction, the bacteria were pelleted by centrifugation (5,000 ϫ g) and resuspended in MENG buffer. The resulting mixture was disrupted using 4 ϫ 15-s sonic pulses on ice and cleared by centrifugation (17,000 ϫ g). The resulting supernatant was cut with 35-45% ammonium sulfate and centrifuged at 17,000 ϫ g. The pellet was washed in ammonium sulfate (45%) and resuspended in MENG buffer. The resulting solution was purified using high performance liquid chromatography on a POROS 10 HQ column using NaCl gradient from 200 -800 mM (PerSeptive Biosystems, Cambridge MA).
Pharmacology in Yeast-AHR dose-response curves were performed in the S. cerevisiae strain L40 as described previously (14) . Two days after plasmid transformation, the colonies were replica plated on media with various concentrations of ␤-NF spread on the surface. The replica plates were then incubated for 2 days at 30°C. For each dose of ␤-NF, three colonies were suspended in 100 l of Z-buffer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 , 35 mM 2-mercaptoethanol) and cell density was estimated by reading the A 600 . Twenty microliters of the remaining cell suspension was added to 130 l of Z-buffer, 25 l of 0.1% SDS (w/v), 25 l of CHCl 3 and disrupted at high speed for 10 s. Thirty microliters of a 4 mg/ml o-nitrophenyl-␤-D-galactoside solution was added and the mixture incubated for 2-5 min at 30°C. The reaction was stopped by adding 75 l of 1 M NaCO 3 , the cell debris removed by centrifugation and the A 420 was determined. ␤-Galactosidase units were determined using the following formula (A 420 /(A 600 of 1/10 dilution of cells ϫ volume of culture ϫ time of incubation)) ϫ 1,000. To examine expression levels of FKBP52 and ARA9 in yeast, we performed Western blot analysis on cell extracts as described previously (19) .
3
H-FK506 Binding Assay-The ARA9 and FKBP52 proteins were purified from 4 g of BL21(DE3) bacterial extract by incubation in the presence of 20 l of T7-agarose in bind/wash buffer for 1 h at 4°C. Samples were washed twice in bind/wash buffer, followed by one wash in 10 mM Tris-HCl, pH 7.5. The resulting protein-agarose pellet was resuspended in 50 l of 10 mM Tris-HCl in the presence of 3 H-FK506 (84 Ci/mmol, NEN Life Science Products Inc.) at 4°C for 3 h. The samples were washed three times in ice-cold 10 mM Tris-HCl, pH 7.5, and the radioactivity quantified by liquid scintillation counting. To demonstrate specificity, the incubation was also performed in the presence and absence of unlabeled FK506, rapamycin, or cyclosporin-A as competitor.
In Situ Hybridization of Mouse Embryonic Tissue-The 1.1-kilobase EcoRI cDNA fragment of PL613 was subcloned into pbSK in the T7 orientation for the generation of sense (NotI digested) and antisense (EcoRI digested) riboprobes. Both sense and antisense riboprobes were generated with 80 Ci of [
35 S]UTP (Amersham, Ͼ1000 Ci/mmol) as the radioactive ribonucleotide and subjected to alkaline hydrolysis for 9 min at 60°C as described (20) . Embryos (sagittal sections) or tissues from adult mice (cross-sections) were cut at 5 m and mounted on "Superfrost-plus"slides (Fisher, Pittsburgh, PA). The processing, hybridization, washing conditions, development, and photography of the slides were performed as described previously (21) . Hoechst dye (Boehringer Manheim) was used as the counterstain.
Chromosomal Localization-Chromosomal localization was performed by a commercial service (SeeDNA Biotech Inc., North York, Ontario, Canada) using the 1.1-kilobase EcoRI fragment from PL613 as a probe. Briefly, lymphocytes isolated from human blood were cultured in ␣-minimal essential medium supplemented with 10% fetal calf serum and phytohemagglutinin at 37°C for 72 h. The lymphocyte cultures were treated with 5-bromodeoxyuridine (0.18 mg/ml) to synchronize the cell population. The synchronized cells were washed three times with serum-free medium to release the block and recultured at 37°C for 6 h in ␣-minimal essential media with thymidine (2.5 g/ml). Cells were harvested and slides were made using a hypotonic treatment procedure, then fixed and air-dried. The probe was biotinylated with dATP using nick labeling. The procedure for FISH detection was performed as described previously (22, 23) . The chromosomal assignment was confirmed using a diagnostic polymerase chain reaction strategy and a panel of DNA samples obtained form human-hamster somatic cell hybrids (Bios, New Haven, CT). Using oligonucleotides OL814 and OL869 a ϳ600-base pair fragment of the human ARA9 gene was amplified from 200 ng of hybrid DNA. To determine the presence of the human gene in the hamster DNA background, each polymerase chain reaction was then analyzed by electrophoresis on a 1% agarose gel and visualized with ethidium bromide for detection of the diagnostic band (24) .
RESULTS

AHR Domains Required for ARA9
Interaction-In order to map the region of the AHR required for interaction with ARA9, co-immunoprecipitation assays were performed using proteins that had been produced by in vitro translation in reticulocyte lysates. 35 S-Labeled ARA9 and a series of deletions of the AHR were mixed and immunoprecipitated with antibodies specific to the basic region (G1295) or the PAS domains (BEAR-1) of the AHR (Fig. 1) . We observed that an NH 2 -terminal deletion of 130 amino acids (AHRN⌬130) but not 287 residues (AHRN⌬287) was able to form complexes with ARA9. COOHterminal deletions of the AHR of up to 313 amino acids (AHRC⌬313) also associated with ARA9, while COOH-terminal deletions of 425 amino acids (AHRC 425) or greater did not associate with the AHR. This defines the approximate boundaries of the AHR domain required for ARA9 interaction as lying between amino acids 130 and 491. These approximate boundaries are supported by the observation that an AHR construct containing an internal deletion in this region, AHR⌬290 -491, does not co-immunoprecipitate ARA9 in parallel experiments.
ARA9 Domains Required for Interaction with AHR and Hsp90 -To map the region of ARA9 that is required for interaction with the AHR, two ARA9 mutants that had been T7-tagged were expressed in bacteria and affinity purified. The ARA9⌬C mutant contains the NH 2 -terminal amino acids 1-174 corresponding to the FKBP12 homology domain. The ARA9⌬N mutant contains the carboxyl-terminal portion of ARA9 (amino acids 154 -330) and includes the three TPR domains (Fig. 2 (7) ). These proteins were tested for their ability to interact with 35 S-labeled AHR and Hsp90 in co-immunoprecipitation assays using anti-T7 tag antibodies. In these assays, the COOH-terminal TPR domains of ARA9 were capable of precipitating both Hsp90 and AHR, while the NH 2 -terminal FKBP domain showed no activity above background (Fig. 2, A and B) . SDS-PAGE analysis indicated that the two mutant ARA9 proteins were expressed to equivalent degrees, arguing against differences in protein expression as an explanation of the differential interaction (Fig. 2C) .
Specificity of ARA9 for AHR-The structural similarity between ARA9 and FKBP52 led us to compare the relative capacity of these two factors to bind AHR. To determine their relative binding, T7-tagged ARA9 or FKBP52 (expressed in bacteria) were incubated in the presence of 35 S-labeled AHR (expressed in reticulocyte lysates). The AHR-ARA9 or AHR-FKBP52 associations were determined by co-immunoprecipitation with T7-agarose. In this system, ARA9 was approximately four times more efficient at precipitating AHR than was FKBP52 (Fig. 3A) . To demonstrate that these results were not due to an inability of FKBP52 to function in this system, or to a lower expression level, we performed a positive control and measured the capacity of ARA9 and FKBP52 to associate with Hsp90. We observed that under the same conditions as those used to assay AHR interactions, FKBP52 exhibited a 4-fold greater capacity to interact with 35 S-labeled Hsp90 than did ARA9 (Fig. 3B) .
In a second experiment, we analyzed the relative capacities of AHR and GR to form higher order complexes that included ARA9 and Hsp90. Our previous work using anti-Hsp90 antibodies demonstrated that ARA9 has a much higher affinity for AHR-Hsp90 complexes than for Hsp90 alone. Therefore, we performed co-immunoprecipitation assays with anti-Hsp90 antibodies to determine if ARA9 also had a higher affinity for GR-Hsp90 complexes. In contrast to AHR, GR was incapable of increasing the ARA9-Hsp90 interaction (Fig. 4) .
FK506 Binding-Since the NH 2 -terminal portion of ARA9 contains an "FKBP12 homology domain," it was of interest to determine if ARA9 was also capable of binding the prototype ligand, FK506. To this end, bacterial extracts containing either T7-tagged ARA9 or T7-tagged FKBP52 were assayed for their capacity to bind 3 H-FK506. The extract containing FKBP52 exhibited significant binding to 3 H-FK506 (Fig. 5) . Scatchard analysis revealed that the affinity of this binding displayed a K D of approximately 5 ϫ 10 Ϫ8 M (data not shown). These observations are in agreement with that previously reported for FKBP52 (25, 26) . Structure-activity analysis indicated that this interaction was specific since FK506 binding to FKBP52 could be displaced by co-incubation with unlabeled FK506 or rapamycin. In addition, cyclosporin-A, a macrolide specific for the cyclophilin class of immunophilins, did not compete for these FK506-binding sites (Fig. 5) . In contrast to FKBP52, we could not detect 3 H-FK506 binding to ARA9 at several concentrations of 3 H-FK506 (Fig. 5 and data not shown) . In an effort to increase sensitivity of the FK506 binding assay, the experiment was repeated using 2 g of purified ARA9. Using this purified preparation we were still unable to detect binding of 3 H-FK506 to ARA9 (Fig. 5) .
ARA9 Enhances Ligand Responsiveness of AHR-Given the sequence similarities between ARA9 and FKBP52, we asked if either protein could influence AHR signaling in vivo. To this end, we employed a LexA-AHR chimera and a LexA-operatordriven ␤-galactosidase reporter gene in the yeast S. cerevisiae (14) . ␤-Napthoflavone dose-response curves were constructed for the LexA-AHR in the presence and absence of ARA9 (Fig. 6) . Co-expression of ARA9 significantly enhanced the response of AHR to ␤-NF, decreasing the EC 50 approximately 5-fold when ARA9 was present (Fig. 6 ). In addition, the maximal response to ␤-NF was increased approximately 2.5-fold in the presence of ARA9 (Fig. 6) . In parallel experiments a similar shift in AHR dose-response could not be elicited by FKBP52, nor could either factor alter the response of a GR-LexA chimera to the GR ligand, deoxycorticosterone (Fig. 6) . To rule out the possibility that these results were due to lack of expression of either protein in our yeast model system, yeast extracts were subjected to Western blot analysis and a high level of both ARA9 Preliminary experiments demonstrated that the corresponding deletions were equally immunoprecipitated with these antibodies (data not shown). Proteins were separated on 10% SDS-PAGE, and the co-immunoprecipitated ARA9 was visualized by autoradiography. "Input" is a loading control representing 100% of the radiolabeled ARA9 used in the assay. "PI" is the preimmune control. The ARA9-binding domain deduced from these experiments is described by the bold line.
and FKBP52 were detected (Fig. 6, inset) .
In Situ Hybridization-High levels of ARA9 mRNA were detected in murine embryonic development as early as E9.5 days (Fig. 7) . At E9.5 days, ARA9 mRNA is ubiquitously expressed with higher levels observed in the neuroepithelium, trigeminal ganglion, branchial arches 1 and 2, hepatic primordia, and the primitive gut. In the E13.5 day embryo, ARA9 mRNA remained widespread, with highest levels observed in the derivatives of the branchial arches; thymus, lung, liver, intestines, urogenital sinus, and genital tubercle. Examination of adult lymphoid tissues also revealed high levels of ARA9 mRNA in the thymic cortex and the splenic white pulp.
Chromosomal Localization of ARA9 -To determine the chromosomal localization of the human gene encoding ARA9, 4Ј,6-diamidino-2-phenylindole banding was used to identify the specific chromosome and the detailed position was determined based on the summary of 10 photos. These data localized ARA9 to chromosome 11, region q13.3. Another gene that maps to this region encodes FKBP13 (11q13.1-13.3) (27) . Since, the FKBP13 gene is localized to the same region of chromosome 11 (see "Discussion" below) as the ARA9 gene and since a full-length ARA9 cDNA probe was used in the FISH analysis we confirmed the chromosome 11 localization of ARA9 by an independent polymerase chain reaction protocol. Using polymerase chain reaction probes directed to the 3Ј end of the ARA9 cDNA (outside of the region of sequence homology between ARA9 and FKBP13) we analyzed a somatic cell hybrid panel of genomic DNA derived from human-hamster fusions (Bios). This screen confirmed ARA9's localization to chromosome 11 (data not shown).
DISCUSSION
The AHR and GR signaling pathways display a number of mechanistic similarities (1, 28) . In the absence of agonist, both the AHR and GR are primarily found in a cytosolic complex with a dimer of Hsp90 and a number of smaller proteins (29 -32) . Upon binding their respective ligands, the AHR and GR complexes undergo changes in their oligomeric state, as well as an increased affinity for the nuclear compartment of the cell (32) (33) (34) . While the GR homodimerizes in the nucleus, the AHR heterodimerizes with its cognate partner, ARNT. The resulting dimers bind their respective enhancer elements and activate transcription of target genes (1, 35) . These similarities have prompted us to compare the signal transduction and oligomeric composition of the AHR and GR in the hopes that we can understand aspects of these pathways that are fundamental to both basic helix loop helix-PAS proteins and members of the 
FIG. 2. Characterization of ARA9-AHR interaction and PAS specificity.
A, radiolabeled AHR was incubated in the presence of T7-tagged proteins that had been expressed in bacteria. FL is the full-length ARA9, ⌬N is the NH 2 -terminal truncation of ARA9, ⌬C is the COOH-terminal truncation of ARA9. Ctrl is bacteria lysate from untransformed BL21 cells. All complexes were precipitated with T7-tagged agarose. Proteins were separated on 7.5% gel and visualized by autoradiography. B, radiolabeled Hsp90 was used in a similar assay described in A. C, 4 g of total extracts used in A were separated on a 10% gel and transferred to nitrocellulose. Western blot analysis was preformed using a T7 antibody conjugated to alkaline phosphatase (Novagen). D, diagram of ARA9 in which the FKBP12 homology domain is labeled FKBP and the domain implicated in binding AHR and Hsp90 is noted by the solid line. Input lanes represent 25% of total protein (AHR or Hsp90) used in experiments. Bottom, the bands radioactivity present in the AHR or Hsp90 bands was quantified using a PhosphorImager to make comparisons of relative coimmunoprecipitation. The bars represent the means from three independent experiments. The error bars indicate the standard error of the mean. B, Hsp90 was used in a similar experiment described in A.
steroid/thyroxin receptor superfamily.
Biochemical studies demonstrate that Hsp90 association is correlated with each receptor's capacity to bind ligand, as well as their repressed DNA binding state (36 -40) . Data from a yeast model system support these observations and has been used to demonstrate that Hsp90 is essential for agonist-induced signal transduction in vivo (14, 41, 42) . In addition to Hsp90, the GR-Hsp90 complex has also been shown to contain a molecule of FKBP52, Cyp40, or PP5 (32, (43) (44) (45) (46) . FKBP52 and Cyp40 are often referred to as immunophilins because they bind the immunosuppressant macrolides, FK506 or cyclosporin-A, respectively (47) . In L-cell cytosol, FKBP52-and PP5-containing GR complexes comprise 52 and 35% of the total GR complexes, while CyP40 is found in only a small percentage of GR complexes (46, 48) .
Recently, it has been observed that the AHR-Hsp90 complex contains a 37-kDa protein, ARA9, which displays significant amino acid sequence similarity to FKBP52 (7) (8) (9) . This similarity prompted us to perform a detailed analysis of the AHR-ARA9 interaction. In our first series of experiments, we attempted to define the protein domains required to form the ARA9-Hsp90-AHR complex. To accomplish this, we performed deletion analyses on both ARA9 and AHR and measured the capacity of these mutants to form higher order complexes in vitro. Reticulocyte lysates formed the common milieu for these experiments, since they have been shown to properly fold AHR and are known to contain high levels of Hsp90. In this system, we observed that the TPR domains of ARA9 were both necessary and sufficient to form complexes that contained both AHR and Hsp90 (Fig. 2, A and B) . Conversely, the NH 2 -terminal half of ARA9 did not interact with either protein. In the reciprocal domain mapping experiments, we observed that ARA9 interacts within the AHR's repressor domain (Fig. 1) . This region of the AHR has previously been shown to repress receptor activity and harbor the domains required for both Hsp90 and ligand binding (5, 49 -51) .
The domain mapping studies suggest a tertiary complex where ARA9 interacts with Hsp90 through its TPR domains and Hsp90 interacts with AHR through its repressor domain. Given the influence of AHR on ARA9 association (Fig. 4 (7) ), the linear model predicts that AHR directly alters the structure or activity of Hsp90, which in turn allows ARA9 binding. Al- (64)). Below, schematics of the AHR and GR constructs. Lex is the LexA DNA-binding domain. LBD is the ligand-binding domain. TAD is the transcriptionally active domain.
though this "linear" interaction model has considerable experimental support, it is premature to rule out a more complex model where all proteins are involved in bipartite interactions, i.e. each protein contacts each other protein. For such a model to be correct, the AHR must directly contact ARA9 or additional bridging proteins must exist (52) . Although this has not yet been shown, it may be that direct ARA9-AHR interaction does occur in vivo and simply cannot be detected by the analytical approaches currently in use. If such an interaction does exist, it will be difficult to demonstrate since Hsp90 is required for proper folding of AHR. If the bipartite model was correct, then AHR could have an effect on ARA9 association function through direct contact rather than by influencing the structure of Hsp90.
Although ARA9 and FKBP52 share significant sequence homology and form similar oligomeric complexes, our data suggests that they also have distinct cellular roles and unique biochemical properties. A number of observations support the idea that these proteins harbor interaction specificity for their cognate receptors: 1) ARA9 has a greater affinity than FKBP52 for the AHR-Hsp90 complex; 2) AHR enhances the stability of ARA9-Hsp90 interactions, but does not enhance Hsp90-FKBP52 interactions; 3) GR does not enhance ARA9-Hsp90 interactions; 4) ARA9 expression significantly augments AHR signaling in yeast, yet has no influence on GR signaling. An additional distinguishing feature of ARA9 is in its capacity to bind macrolides such as FK506. The conclusion that ARA9 does not bind FK506 was based upon our inability to detect 3 H-FK506 binding to ARA9, while binding to FKBP52 was easily measured. Although it is difficult to prove a negative result, the lack of FK506 binding to ARA9 was anticipated based upon the observation that of the 14 residues in FKBP12 thought to contact FK506, only 5 are conserved in ARA9 (7) . Taken in sum, these results clearly document unique biochemical properties of ARA9 and FKBP52, as well as suggest that each protein plays an important role in signal transduction by distinct classes of ligand activated transcription factors.
The mechanism by which immunophillins influence GR signaling is still somewhat unclear. Other than physical association, the evidence for a functional role of these proteins is based upon a number of experimental lines of evidence. First, the importance of FKBP52 and Cyp40 in GR signal transduction is suggested by experiments where FK506 or cyclosporin-A have been shown to augment GR signal transduction in mammalian cells and yeast (53) (54) (55) (56) . Second, yeast strains devoid of the CYP40 homologue CPR7 exhibit deficient glucocorticoid receptor signaling (57) . Interestingly, recent evidence has indicated that the CPR7 dependent activity of GR can be rescued by a FIG. 7 . In situ hybridization of ARA9 in E9.5, E13.5 mice, and adult thymus and spleen. In situ hybridization was performed using a full-length ARA9 probe as described under "Materials and Methods." mutant cDNA that harbors only the TPR domains and is devoid of any cyclosporin-A binding or peptidylprolyl cis-trans isomerase activity (58) . Although the idea that peptidylprolyl cis-trans isomerase activity is unrelated to GR signaling is not new, the dominance of the TPR domain in this rescue experiment suggests that immunophillins and their corresponding immunosuppressants may be acting by multiple mechanisms.
In a similar manner, we have demonstrated that expression of ARA9 has a functional consequence on AHR signal transduction. Co-expression of ARA9 in a yeast model system significantly increases both the sensitivity and the maximal response of AHR to agonist (Fig. 6) . Although the molecular basis for this effect in yeast has yet to be determined, it is supported by recent experiments in mammalian cell culture (8, 9) . Interestingly, the effect of ARA9 on the ␤-NF dose-response curve of AHR is what would be predicted under conditions of increased receptor number (59) . Put in its broadest context, our data are consistent with ARA9 increasing the number of receptors that bind agonist at a given dose or the number of receptors that can progress through a rate-limiting step in signal transduction. Although Western blots to approximate AHR expression in yeast extracts do not indicate any influence of ARA9 on total AHR protein levels (data not shown); these results should not be over-interpreted since we do not yet know what percentage of AHR is properly folded under each condition. In this regard, it is important to note that the data from the GR system suggests that FKBP52 influences GR trafficking to the nucleus and does not necessarily increase total receptor number (60) . A similar mechanism may be at play for ARA9-AHR.
It is tempting to speculate that the physical interaction between the AHR and ARA9 is mechanistically related to their functional interaction at the level of enhanced AHR signal transduction (Fig. 6) (8, 9) . In an effort to present a more balanced discussion of this point, it is important to consider a series of experiments from the GR field. Recent evidence has suggested that FK506 may influence GR signaling in yeast and mammalian cells by inhibiting a membrane transporter with specificity to pump certain glucocorticoids out of the cell (61, 62) . These results suggest that FK506's action may not be mediated by direct interaction with the FKBP52-GR complex, but rather may be mediated through interaction with the yeast transporter, Pdr5p, or with a yeast FKBP that influences this transporters activity. By extension, one could argue that ARA9's affect on AHR signal transduction may be mediated indirectly through inhibition of a drug-transporter like Pdr5p. Although we have not yet formally ruled out the possibility that ARA9 inhibits "␤-NF transporters," the pharmacological profile argues against this. If ARA9 expression was inhibiting a transporter and increasing the intracellular concentration of ␤-NF, we would predict a "left-shift" in the dose-response curve, but not an increase in the maximal response (i.e. an increase in apparent potency, but not in apparent efficacy of the agonist). Additionally, since we did not use FK506 in our experiments, competition for the pump's activity by the macrolide can be ruled out.
Finally, the developmental expression of ARA9 also has a number of important implications. A comparison of the developmental profiles of AHR and ARA9 suggests that ARA9's function is probably not restricted to AHR signal transduction (compare Fig. 7 to results in Ref. 63 ). For example, ARA9 is highly expressed at E9.5, before high levels of AHR are detected, and ARA9 is more widely expressed than the AHR at later time points like E13.5 and into adulthood (63) . The observation that AHR and ARA9 expression are coincident at a number of sites (e.g. thymus, liver, and lung) supports the biological relevance of the interaction. Moreover, if ARA9 augments AHR signaling, its level of expression may play an important role in the tissue specific sensitivity of certain tissues like thymus.
